Within labeled indications, drug-eluting stents (DES) are as safe as bare-metal stents (BMS). Data from key randomized, controlled trials comparing paclitaxel-eluting stents with BMS or sirolimus-eluting stents with BMS ...
A weti-publicized presentation at the 2006 meeting of the World Congress of Cardiology (WCC) raised questions about the safety of drug-eluting stents (DES), leading to a rapid change in clinical practices for patients un...
Accumulating data on the safety and efficacy of first-generation drug-eluting stents (DES) show a favorable risk/benefit profile compared with bare-metal stents (BMS). A recently reported collaborative network meta-analy...
Although the benefits of drug-eluting stents for the treatment of native coronary lesions in patients undergoing percutaneous coronary interventions have been demonstrated in multiple clinical trials, there remains conce...
Resistance to the antiplatelet effects of both aspirin and clopidogrel is common and is associated with poorer clinical outcomes in patients receiving antiplatelet therapy. Available data indicate that hyporesponsiveness...